Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutic (NQ: HALO )

56.87 +6.30 (+12.46%)
Streaming Delayed Price Updated: 12:13 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutic

< Previous 1 2 3 4 5 6 7 8 9 Next >
Amazon Posts Upbeat Results, Joins Cardinal Health, Waters, Atlassian, Charter Communications, MasTec And Other Big Stocks Moving Higher On Friday
Via Benzinga
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Investors seeking growth at a reasonable cost should explore NASDAQ:HALO.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is showing good growth, while it is not too expensive. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
A Look Ahead: Halozyme Therapeutics's Earnings Forecast
Via Benzinga
Unveiling 12 Analyst Insights On Halozyme Therapeutics
Via Benzinga
Investors should take notice of NASDAQ:HALO—it offers a great deal for the fundamentals it presents.
For those who appreciate value investing, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a compelling option with its solid fundamentals. 
Via Chartmill
Exploring the Growth Potential of NASDAQ:HALO as It Nears a Breakout.
Exploring the Growth Potential of HALOZYME THERAPEUTICS INC (NASDAQ:HALO) as It Nears a Breakout. 
Via Chartmill
Despite its growth, NASDAQ:HALO remains within the realm of affordability.
Despite its growth, NASDAQ:HALO remains within the realm of affordability. 
Via Chartmill
Despite its impressive fundamentals, NASDAQ:HALO remains undervalued.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is an undervalued gem with solid fundamentals. 
Via Chartmill
A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 12 Analysts
Via Benzinga
NASDAQ:HALO is showing good growth, while it is not too expensive.
Investors should take note ofHALOZYME THERAPEUTICS INC (NASDAQ:HALO), a growth stock that remains attractively priced. 
Via Chartmill
(HALO) - Analyzing Halozyme Therapeutics's Short Interest
Via Benzinga
NASDAQ:HALO is not too expensive for the growth it is showing.
NASDAQ:HALO is showing good growth, while it is not too expensive. 
Via Chartmill
Top 2 Health Care Stocks That May Plunge In August
Via Benzinga
How Is The Market Feeling About Halozyme Therapeutics?
Via Benzinga
NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
Critical Insights From Halozyme Therapeutics Analyst Ratings: What You Need To Know
Via Benzinga
NASDAQ:HALO is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
HALOZYME THERAPEUTICS INC (NASDAQ:HALO): good value for what you're paying. 
Via Chartmill
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
After Monday's panicked global sell-off, markets have calmed down. 
Via Investor's Business Daily
(HALO) - Analyzing Halozyme Therapeutics's Short Interest
Via Benzinga
Looking for growth without the hefty price tag? Consider NASDAQ:HALO.
Investors should take note ofHALOZYME THERAPEUTICS INC (NASDAQ:HALO), a growth stock that remains attractively priced. 
Via Chartmill
Why NASDAQ:HALO Is a Promising High-Growth Stock in the Midst of Consolidation.
Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Beats Revenue for Q2 2024
HALO stock results show that Halozyme Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts
Halozyme and Ligand beat second-quarter expectations late Tuesday. But only one of the biotech stocks jumped. 
Via Investor's Business Daily
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82
On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82. 
Via Investor's Business Daily
NASDAQ:HALO is probably undervalued for the fundamentals it is displaying.
When you look at HALOZYME THERAPEUTICS INC (NASDAQ:HALO), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
3 Biotech Stocks on Track for 50% Returns (or More) by 2028
Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028! 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.